Press release
Skin Cancer Drugs Market is growing at a CAGR of 10.2%, Melanoma dominate 48% of market share | Key Players:- Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd.
Skin Cancer Drugs
The skin cancer drugs market is growing due to rising global skin cancer incidence, increased UV exposure, growing awareness and early diagnosis, strong adoption of immunotherapies and targeted therapies, expanding approvals, and higher healthcare spending in developed and emerging markets.
Download your exclusive free sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/skin-cancer-drugs-market?pratik
United States: Key Industry Developments:-
✅ October 2025: A leading pharmaceutical company launched a novel immunotherapy drug targeting advanced melanoma, enhancing patient outcomes through improved immune response activation and reduced side effects in clinical trials.
✅ September 2025: Sanofi and Regeneron expanded indications for Dupixent, gaining FDA clearance for additional skin cancer-related disorders beyond initial approvals, broadening treatment access for non-melanoma cases.
✅ August 2025: Bristol-Myers Squibb advanced late-stage trials for subcutaneous nivolumab formulations in skin cancer, focusing on melanoma and solid tumors to improve clinic efficiency and patient convenience.
Japan: Key Industry Developments:-
✅ October 2025: Japanese regulators approved expanded use of imported immunotherapies like PD-1 inhibitors for metastatic skin cancers, aligning with global trends in monoclonal antibody adoption.
✅ September 2025: Local biotech firms partnered with international players for BRAF/MEK inhibitor combinations targeting melanoma, accelerating access to precision therapies amid rising incidence rates.
✅ August 2025: Government subsidies supported clinical pipelines for oncolytic viruses in non-melanoma skin cancer, promoting domestic innovation in novel vaccine-based treatments.
→ 2025 M&A Activity:-
March 10, 2025: Sun Pharmaceutical Industries agreed to acquire Checkpoint Therapeutics a U.S. immunotherapy and targeted oncology company - in a deal valued at approximately $355 million, bringing the FDA-approved skin cancer drug UNLOXCYT (cosibelimab-ipdl) into Sun Pharma's global oncology portfolio and expanding its onco-dermatology treatments.
"Secure your 30% year-end discount - get this report before the offer expires.":https://www.datamintelligence.com/buy-now-page?report=skin-cancer-drugs-market?pratik ((Purchase 2 or more Repots and get 50% Discount)
→ Market Segmentation-
Cancer Type Segments:-
Melanoma: 48% market share in 2025, driven by high mortality and strong uptake of immunotherapies.
Basal Cell Carcinoma (BCC): 25% share, supported by hedgehog inhibitors and targeted drugs.
Squamous Cell Carcinoma (SCC): 17% share, aided by expanding systemic treatment use.
Merkel Cell Carcinoma: 5% share, growing rapidly due to immunotherapy adoption.
Other Skin Cancers: 5% share from niche and rare indications.
Drug Class Segments
Immunotherapy: 42% market share, led by checkpoint inhibitors and combination regimens.
Targeted Therapy: 30% share, driven by BRAF/MEK and hedgehog inhibitors.
Chemotherapy: 23% share, sustained by legacy use in advanced cases.
Others: 5% share, including photodynamic and adjunct therapies.
End-User Segments
Hospitals: 58% market share, dominating due to complex inpatient treatments.
Clinics: 24% share, supported by outpatient oncology services.
Cancer Research Institutes: 12% share, driven by clinical trials and innovation.
Others (specialty pharmacies, etc.): 6% share, growing with decentralized care.
→ 🌍 Skin Cancer Drugs Market - Regional Insights
North America - 42% Market Share
North America is the largest region in the skin cancer drugs market, driven by advanced healthcare infrastructure, early adoption of innovative therapies, high awareness levels, and supportive reimbursement policies.
Europe - 30% Market Share
Europe holds a significant portion, supported by robust healthcare systems, rising prevalence of skin cancer, and continued investment in research and development of novel drug therapies.
Asia-Pacific - 20% Market Share
Asia-Pacific is a fast-growing market with expanding healthcare access, increasing awareness of early diagnosis, and improving treatment availability across China, Japan, India, and Australia.
Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/skin-cancer-drugs-market?pratik
→ Market Players:-
Some of the key players contributing to the market's growth include Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd, Daiichi Sankyo Co., GlaxoSmithKline, among others.
Bristol-Myers Squibb Company
Bristol-Myers Squibb leads with Opdivo (nivolumab), a PD-1 inhibitor widely used for advanced melanoma, capturing an estimated 25-30% market share in 2025 due to strong efficacy in immunotherapy combinations and expanded indications. The company's dominance stems from robust clinical trial data showing improved survival rates in BRAF-mutated and non-mutated skin cancers. Ongoing partnerships enhance its position in targeted therapies.
F. Hoffmann-La Roche Ltd
Roche follows closely with Tecentriq (atezolizumab) and Avastin (bevacizumab) combinations, holding about 20-25% market share in 2025, bolstered by approvals for adjuvant melanoma treatment and next-generation sequencing diagnostics. Its strength lies in integrated immuno-oncology platforms and global reach in precision medicine for non-melanoma skin cancers like cutaneous squamous cell carcinoma. Roche's R&D investments in bispecific antibodies further solidify its leadership.
Merck & Co., Inc.
Merck secures third place with Keytruda (pembrolizumab), commanding 15-20% market share in 2025, thanks to first-line approvals for resectable melanoma and superior outcomes in PD-L1 positive cases. Keytruda's versatility across skin cancer stages, combined with Merck's aggressive expansion into adjuvant settings, drives its growth amid rising incidence rates
→ Key market drivers (skin cancer drugs):-
Rising incidence of skin cancers - Increasing melanoma and non-melanoma cases worldwide (more diagnoses → greater drug demand).
Wider adoption of immunotherapies - PD-1/PD-L1 and CTLA-4 checkpoint inhibitors are replacing older modalities and expanding indications.
Targeted therapy advances (BRAF/MEK, etc.) - Effective targeted agents for molecular subtypes improve outcomes and raise treatment uptake.
Robust R&D and venture funding - Large investments and biotech innovation bringing novel combos and next-gen immunotherapies.
Regulatory approvals & new formulations - Recent approvals and convenience formulations (e.g., subcutaneous versions of blockbuster agents) improve access and outpatient use.
Better diagnostics & biomarker testing - Wider use of genomic and PD-L1 testing enables precision prescribing and expands eligible patient pools.
Aging populations and demographic shifts - Older populations with higher lifetime sun exposure raise incidence and chronic treatment needs.
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Skin Cancer Drugs Market is growing at a CAGR of 10.2%, Melanoma dominate 48% of market share | Key Players:- Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. here
News-ID: 4314807 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Location Analytics Tools Market to hit US$ 49.1 billion by 2030: Growth in GCC a …
Location Analytics Tools market reached US$ 18.5 billion in 2022 and is expected to reach US$ 49.1 billion by 2030 growing with a CAGR of 13.0% during the forecast period 2023-2030.
Get Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/location-analytics-tools-market?kb
United States: Recent Industry Developments
✅ November 2025: ESRI enhanced its location analytics platform with AI-driven predictive insights for retail and urban planning use cases.
✅ October…
Cardiovascular Ultrasound System Market to Reach US$ 3.9 Billion by 2032 at 8.1% …
The Global Cardiovascular Ultrasound System Market reached US$ 2.1 billion in 2024 and is expected to reach US$ 3.9 billion by 2032, growing at a CAGR of 8.1% during the forecast period 2025-2032. The market is expanding steadily due to the rising prevalence of cardiovascular diseases, increasing demand for early and non-invasive diagnostic procedures, and growing adoption of advanced imaging technologies in hospitals and diagnostic centers.
Cardiovascular ultrasound systems, including echocardiography…
Batter and Breader Premixes Market Set for Steady Growth at 6.2% CAGR During Thr …
The Global Batter and Breader Premixes Market is expected to grow at a steady CAGR of 6.2% during the forecast period 2024-2031.
Market growth is driven by rising demand for processed and convenience foods, increasing consumption of fried and coated meat and seafood products, and the expanding quick-service restaurant (QSR) sector. Additionally, innovation in clean-label, gluten-free, and customized premix formulations, along with growing urbanization and changing dietary habits, is further supporting…
Basalt Fiber Market Forecast to Expand at 14.7% CAGR Through 2031, Reaching USD …
The Global Basalt Fiber Market reached US$ 375 million in 2023 and is projected to reach US$ 1,120 million by 2031, growing at a CAGR of 14.7% during the forecast period 2024-2031. The market is expanding steadily as basalt fiber gains traction as a cost-effective, high-performance alternative to carbon and glass fibers across multiple industries.
Growth is driven by increasing adoption in construction, automotive, aerospace, wind energy, and marine applications due…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
